Zhang Lei, Hu Rong, Cheng Yanyong, Wu Xiaoyang, Xi Siwei, Sun Yu, Jiang Hong
Department of Anesthesiology, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Center for Specialty Strategy Research of Shanghai Jiao Tong University China Hospital Development Institute, Shanghai, China.
Cell Prolif. 2017 Oct;50(5). doi: 10.1111/cpr.12364. Epub 2017 Jul 24.
Lidocaine is the most commonly used local anaesthetic in clinical and can inhibit proliferation, suppress invasion and migration and induce apoptosis in human lung adenocarcinoma (LAD) cells. However, its specific downstream molecular mechanism is unclear.
LAD cell lines, A549 and H1299 cells, were treated with lidocaine. The proliferation was evaluated by the methylthiazolyldiphenyl-tetrazolium bromide (MTT) and bromodeoxyuridine (BrdU) assay. The expression level of related proteins was detected by real-time quantitative PCR (qPCR) and Western blot assay.
The results indicated that lidocaine dose-dependently suppressed the proliferation of A549 and H1299 cells. In the LAD patients' samples, GOLT1A was upregulated and involved in the poor prognosis and higher grade malignancy. Additionally, GOLT1A mediates the function of lidocaine on repressing proliferation by regulating the cell cycle in A549 cells.
Our findings suggest that lidocaine downregulates the GOLT1A expression to repress the proliferation of lung cancer cells.
利多卡因是临床最常用的局部麻醉药，可抑制人肺腺癌（LAD）细胞增殖、抑制侵袭和迁移并诱导其凋亡。然而，其具体的下游分子机制尚不清楚。
用利多卡因处理LAD细胞系A549和H1299细胞。通过甲基噻唑基二苯基溴化四氮唑（MTT）和溴脱氧尿苷（BrdU）检测法评估细胞增殖情况。通过实时定量聚合酶链反应（qPCR）和蛋白质免疫印迹法检测相关蛋白的表达水平。
结果表明，利多卡因可剂量依赖性地抑制A549和H1299细胞的增殖。在LAD患者样本中，高尔基体运输蛋白1A（GOLT1A）上调，与预后不良和更高等级的恶性肿瘤有关。此外，GOLT1A通过调节A549细胞的细胞周期介导利多卡因抑制增殖的功能。
我们的研究结果表明，利多卡因通过下调GOLT1A的表达来抑制肺癌细胞的增殖。
